
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladder cancer. FDA And EU Clear Klygefa For Generalized Myasthenia Gravis Monday, the U.S. Food and Drug Administration and EU authorities approved Klygefa (gefurulimab)…
Source: Read the full story at Top Stories Feed
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.